STOCK TITAN
  1. Home
  2. News
  3. 2020-12-06

Stock Market News 2020-12-06

29 news published.

2020-12-05 2020-12-07
IMPACT
SENTIMENT
12/06/2020 11:00 PM
ATRA : Nasdaq
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
IMPACT
SENTIMENT
12/06/2020 09:50 PM
IGT : NYSE APO : NYSE
International Game Technology PLC Announces Agreement To Sell Italian B2C Gaming Business For €950 Million In Cash
IMPACT
SENTIMENT
12/06/2020 09:45 PM
NNDM : Nasdaq
Nano Dimension Prices $180 Million Registered Direct Offering
offering
IMPACT
SENTIMENT
12/06/2020 08:00 PM
JEF : NYSE
Jefferies Announces Co-Brand Alliance with KB Securities in South Korea
IMPACT
SENTIMENT
12/06/2020 06:30 PM
SVA : Nasdaq
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
covid-19
IMPACT
SENTIMENT
12/06/2020 06:03 PM
PCG : NYSE
Potential PSPS Update: Due to Improved Weather Conditions, Scope of Public Safety Power Shutoff Significantly Reduced. PG&E May Still Proactively Turn Off Power for Safety in Targeted Portions of Five Counties Beginning Early Monday Morning
IMPACT
SENTIMENT
12/06/2020 05:00 PM
XNCR : Nasdaq
Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/06/2020 05:00 PM
SSNC : Nasdaq
Fortlake Selects SS&C to Support Fixed Income Operations
IMPACT
SENTIMENT
12/06/2020 03:30 PM
VEEV : NYSE
GenesisCare Clinical CRO Adopts Veeva Vault Clinical Applications to Accelerate and Scale Studies Globally
IMPACT
SENTIMENT
12/06/2020 03:00 PM
GILD : Nasdaq
Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
IMPACT
SENTIMENT
12/06/2020 02:45 PM
PTGX : Nasdaq
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
clinical trial
IMPACT
SENTIMENT
12/06/2020 01:00 PM
ABBV : NYSE
Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients
clinical trial
IMPACT
SENTIMENT
12/06/2020 01:00 PM
MGNX : Nasdaq
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
IMPACT
SENTIMENT
12/06/2020 12:30 PM
KDMN : NYSE
Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting
IMPACT
SENTIMENT
12/06/2020 12:30 PM
GILD : Nasdaq
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
clinical trial
IMPACT
SENTIMENT
12/06/2020 12:30 PM
BGNE : Nasdaq
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/06/2020 12:30 PM
CTIC : Nasdaq
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting
IMPACT
SENTIMENT
12/06/2020 12:30 PM
SNDX : Nasdaq
Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD
clinical trial
IMPACT
SENTIMENT
12/06/2020 10:05 AM
FATE : Nasdaq
Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma
IMPACT
SENTIMENT
12/06/2020 10:00 AM
RCKT : Nasdaq
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/06/2020 10:00 AM
AZN : NYSE
CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma
IMPACT
SENTIMENT
12/06/2020 10:00 AM
GBT : Nasdaq
GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition
IMPACT
SENTIMENT
12/06/2020 10:00 AM
ALLO : Nasdaq
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
clinical trial
IMPACT
SENTIMENT
12/06/2020 10:00 AM
CRVS : Nasdaq
Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition
IMPACT
SENTIMENT
12/06/2020 10:00 AM
ADPT : Nasdaq
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
clinical trial
IMPACT
SENTIMENT
12/06/2020 10:00 AM
GBT : Nasdaq
GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601
IMPACT
SENTIMENT
12/06/2020 10:00 AM
BCRX : Nasdaq
BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
IMPACT
SENTIMENT
12/06/2020 08:30 AM
CRDF : Nasdaq
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
IMPACT
SENTIMENT
12/06/2020 08:00 AM
CNST : Nasdaq
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
2020-12-05 2020-12-07